Immunoprecipitation.
(A) Human RPE cell extracts were applied with aflibercept- or normal IgG-immobilized protein G beads. A single protein band around 14 kDa was detected (arrow). (B) Co-IP of human RPE cell extracts using aflibercept was performed, followed by SDS-PAGE and immunoblot (IB) analyses for galectin-1.
Western Blotting.
All tested VEGF-A-binding agents (aflibercept, ranibizumab or bevacizumab) completely restored claudin-1 whereas the chimeric antibody rituximab, used as a control to confirm specificity, did not.
ELISA Binding properties to VEGF. Binding to VEGF in ELISA for titrated amounts (1000–0.5?ng/mL) of aflibercept at D0 (black) and D7 (blue).
Schmid, BC; Oehler, MK; et al. New perspectives in ovarian cancer treatment. MATURITAS 77:128-136(2014).
Falchook, GS; Wheler, JJ; et al. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS 33:215-224(2015).
Immunoprecipitation.
(A) Human RPE cell extracts were applied with aflibercept- or normal IgG-immobilized protein G beads. A single protein band around 14 kDa was detected (arrow). (B) Co-IP of human RPE cell extracts using aflibercept was performed, followed by SDS-PAGE and immunoblot (IB) analyses for galectin-1.
Western Blotting.
All tested VEGF-A-binding agents (aflibercept, ranibizumab or bevacizumab) completely restored claudin-1 whereas the chimeric antibody rituximab, used as a control to confirm specificity, did not.
ELISA Binding properties to VEGF. Binding to VEGF in ELISA for titrated amounts (1000–0.5?ng/mL) of aflibercept at D0 (black) and D7 (blue).
My Review for Human Anti-Human VEGF (Aflibercept) Monoclonal Antibody, clone Aflibercept [Biosimilar]
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.